RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

They also can help lower blood sugar and protect heart health. The drugs work in different ways in the body to cause these ...

This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

Structure Therapeutics Inc. has selected a lead oral ... that is being evaluated for use either alone or in combination with glucagon-like peptide-1 (GLP-1) receptor agonists.

Among these compounds, flavonoids—responsible for the vibrant colors in fruits—have drawn attention due to their ability to interact with bitter taste receptors in the gut. These compounds are ...

Researchers from SIT Japan used advanced molecular docking simulations to illustrate how polyphenols, especially flavonoids, bind to the T2R46 receptor ... of glucagon-like peptide-1 (GLP-1 ...